Praxis Precision Medicines (NASDAQ: PRAX) CEO reports tax share withholding

Rhea-AI Filing Summary

Praxis Precision Medicines Chief Executive Officer Marcio Souza reported an automatic share disposition related to tax withholding. On January 7, 2026, 405 shares of common stock were withheld by the company at a price of $292.63 per share to satisfy tax obligations tied to the vesting of previously reported restricted stock units. This was not an open-market sale. After this transaction, Souza beneficially owned 53,502 common shares directly and an additional 2,600 common shares indirectly, which are held by his spouse.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Souza Marcio

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		F(1)		405	D	$292.63	53,502	D
Common Stock								2,600	I	Held by spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PRAX CEO Marcio Souza report?

Marcio Souza reported that 405 shares of Praxis Precision Medicines common stock were withheld by the issuer on January 7, 2026 to cover tax obligations related to vesting restricted stock units.

At what price were the 405 PRAX shares withheld for taxes?

The 405 withheld shares of Praxis Precision Medicines common stock were valued at $292.63 per share in connection with satisfying tax withholding obligations.

How many Praxis Precision Medicines (PRAX) shares does the CEO hold after this transaction?

After the reported transaction, Marcio Souza beneficially owned 53,502 shares of PRAX common stock directly and 2,600 shares indirectly, which are held by his spouse.

Was the PRAX CEO’s Form 4 transaction an open-market sale?

No. The filing explains that the 405 shares were withheld by the issuer to satisfy tax withholding obligations tied to vesting restricted stock units, rather than sold in an open-market transaction.

How are the CEO’s spouse’s PRAX shares reported in this Form 4?

The Form 4 shows an indirect holding of 2,600 shares of Praxis Precision Medicines common stock, noted as "Held by spouse", which are reported as indirectly beneficially owned by Marcio Souza.

What is the transaction code used for the PRAX CEO’s tax withholding event?

The transaction uses code "F", which indicates shares were withheld to pay taxes in connection with the vesting of equity awards.